| Literature DB >> 30698354 |
Abstract
Takayasu arteritis (TA), despite being classified as a large vessel vasculitis, has distinct genetic, pathological and clinical features as compared to giant cell arteritis. It is a rare disease seen more commonly in Asian countries. The challenge lies in assessing the degree of inflammation in a narrowed vessel and immunosuppressive therapy improves inflammatory features but is unable to open up an occluded vessel. It may have a positive effect on retarding further occlusion. Like antineutrophil cytoplasmic antibody-associated vasculitis, TA needs a collaborative effort to do randomized controlled therapy to provide benefit to patients.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30698354 DOI: 10.1111/1756-185X.13383
Source DB: PubMed Journal: Int J Rheum Dis ISSN: 1756-1841 Impact factor: 2.454